Table 1.
Patient characteristics
| Variable | Sirolimus/MMF n=37 N (%) |
CSA/MMF n=123 N (%) |
P-value* | |
|---|---|---|---|---|
| Age (years) | Median (range) | 61 (22–69) | 53 (21–69) | <0.01 |
| Male | 28 (76) | 74 (60) | 0.09 | |
| Year of HCT | <0.01 | |||
| 2006–2009 | 0 (0) | 98 (80) | ||
| 2010–2014 | 37 (100) | 25 (20) | ||
|
HLA disparity (worst match) |
4/6 | 20 (60) | 59 (49) | 0.42 |
| 5/6 | 14 (38) | 53 (43) | ||
| 6/6 | 3 (8) | 11 (9) | ||
|
ATG in conditioning |
17 (46) | 48 (39) | 0.45 | |
| Diagnosis | 0.40 | |||
| Acute leukemia | 17 (46) | 55 (45) | ||
| Lymphoma | 6 (16) | 32 (26) | ||
| Other† | 14 (38) | 36 (29) | ||
| Disease risk | 0.68 | |||
| Standard | 16 (43) | 58 (47) | ||
| High | 21 (57) | 65 (53) | ||
| Prior Auto-HCT | 6 (16) | 26 (21) | 0.51 | |
| HCT-CI | <0.01 | |||
| 0 | 11 (30) | 32 (26) | ||
| 1–2 | 15 (41) | 21 (17) | ||
| ≥ 3 | 10 (27) | 67 (55) | ||
| CMV seropositive | 19 (51) | 82 (67) | 0.05 | |
|
Total TNC (×108/kg) |
Median (range) | 0.4 (0.3–0.8) | 0.4 (0.2–0.7) | 0.16 |
|
Total CD34 (×106/kg) |
Median (range) | 0.5 (0.2–1.8) | 0.4 (0.1–1.3) | 0.34 |
*
P-value for between-treatment comparisons. Continuous variables were analyzed by general Wilcoxon test. Categorical variables were analyzed by chi-square.
†
Other includes diagnoses of Myelodysplastic syndromes and plasma cell disorders